STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB) announced that their abstracts for the 58th Annual Meeting of the American Association for Study of Liver Diseases (AASLD) have been published today and are available on Hepatology web site (AASLD). The two abstracts summarize the results from a phase I clinical trial and further preclinical data that will be presented by Medivir and Tibotec, on their investigational compound TMC435350, a hepatitis C protease inhibitor, at AASLD in Boston, Massachusetts, USA on November 6th, 2007. The two posters are titled “Results of a phase I placebo-controlled trial in healthy volunteers to examine safety, tolerability and PK of the protease inhibitor TMC435350 after single and repeated dosing” and “In vitro activity and preclinical PK of a potent HCV NS3/4A serine protease inhibitor, TMC435350”.
